Reinstadler Sebastian Johannes, Klug Gert, Feistritzer Hans-Josef, Metzler Bernhard, Mair Johannes
Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.
Dis Markers. 2015;2015:614145. doi: 10.1155/2015/614145. Epub 2015 Apr 16.
Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additional information for risk stratification. Cardiac troponins I and T are the most sensitive and specific markers of acute myocardial injury. Nonetheless, in order to overcome the remaining limitations of these markers, novel candidate biomarkers sensitive to early stage of disease are being extensively investigated. Among them, copeptin, a stable peptide derived from the precursor of vasopressin, emerged as a promising biomarker for the evaluation of suspected acute myocardial infarction. In this review, we summarize the currently available evidence for the usefulness of copeptin in the diagnosis and risk stratification of patients with suspected acute myocardial infarction in comparison with routine biomarkers.
疑似急性心肌梗死是急诊入院的主要原因之一。在过去十年中，生物标志物彻底改变了疑似急性冠脉综合征患者的管理方式。除了在及时诊断方面提供关键帮助外，生物标志物还为风险分层提供额外信息。心肌肌钙蛋白I和T是急性心肌损伤最敏感和特异的标志物。尽管如此，为了克服这些标志物尚存的局限性，对疾病早期敏感的新型候选生物标志物正在被广泛研究。其中，copeptin，一种源自血管加压素前体的稳定肽，成为评估疑似急性心肌梗死的一种有前景的生物标志物。在本综述中，我们总结了与常规生物标志物相比，copeptin在疑似急性心肌梗死患者诊断和风险分层中的有用性的现有证据。
